|
Synonyms: compound 41 [PMID: 26704267] | Ruiming® (China) | SHR-4640 | SHR4640
ruzinurad is an approved drug
Compound class:
Synthetic organic
Comment: Ruzinurad (SHR-4640) is a selective, orally bioavailable urate anion exchanger 1 (URAT1; SLC22A12) inhibitor [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Ruzinurad (SHR-4640) was progressed as a clinical candidate for the treatment of hyperuricemia. First approval for this indication was granted by China's NMPA in May 2026 [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04052932 | A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout | Phase 3 Interventional | Jiangsu HengRui Medicine Co., Ltd. | ||
| NCT04956432 | A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout | Phase 3 Interventional | Jiangsu HengRui Medicine Co., Ltd. | ||
| NCT07362355 | The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | Phase 2 Interventional | Jiangsu HengRui Medicine Co., Ltd. | ||
| NCT03185793 | Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia | Phase 2 Interventional | Jiangsu HengRui Medicine Co., Ltd. | 1 | |